New aspects in antidemential drug therapy of Alzheimer's disease;Neue aspekte in der antidementiven pharmakotherapie der Alzheimer-erkrankung

Aktuelle Neurologie

Volumn 27, Issue 7, 2000, Pages 305-317

  Frey, U ^a   Retz, W ^a   Riederer, P ^b   Rosler, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; ESTROGEN; GINKGO BILOBA EXTRACT; SELEGILINE; VITAMIN;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; COGNITION; DISEASE COURSE; GLYCATION; HEREDITY; HUMAN; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RISK FACTOR;

EID: 0033826023     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017557     Document Type: Review

References (195)

1. Alzheimer's disease
2. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to aging and to the accumulation of lipofuscin pigment
3. Observations on the brain of demented old people
4. A double-blind, placebo-controlled, multicenter study of tacrin for Alzheimer's disease
5. A controlled trial of tacrine in Alzheimer's disease
6. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
7. The efficacy and safety of domezepil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donezepil study group
8. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease
9. A double-blind, placebo-controlled trial of high-dose lecithin in Alzheimer's disease
10. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease
11. Treating Alzheimer's disease. Pharmacologic options now and in the near future
12. Muscarinic agonists in Alzheimer's disease
13. Treatment of Alzheimer's disease with cholinergic drugs
14. Cholinergic therapy in dementia
15. Transdermal physostigmin in the treatment of Alzheimer's disease
16. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer's type
17. The effect of long-term physostigmine administration in Alzheimer's disease
18. Treating Alzheimer's disease. Pharmacologic options now and in the near future
19. Beispiele klinischer Prufmodelle fur den Wirksamkeitsnachweis von Nootropika
20. A controlled trial of tacrine in Alzheimer's disease
21. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
22. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4(85,6-dimenthoxy-1-indanon)-2-yl methylpiperidine hydrochloride (E2020)
23. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(15,6-dimethhoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds
24. The pharmacology of a piperidine cholinesterase inhibitor
25. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase
26. Therapeutic standards in Alzheimer disease
27. Coadministration of donepezil HCL and digoxin produces no pharmacokinetic or pharmacodynamic interactions
28. The pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin are uneffected by coadministration of donepezil HCL
29. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects
30. A 24-week, double-blind, placebo-controlled trial of Donezepil in patients with Alzheimer's disease
31. The effects of donezepil in Alzheimer's disease - Results from a multinational trial
32. Long-term efficacy and safety of donezepil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
33. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
34. Cholinesterase inhibitors: An overview of their mechanisms of actions
35. Molecular forms of acetylcholinesterase in subcortical areas of normal and demented (Alzheimer-typ) patients
36. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
37. Measurement of quality-of-life changes in patients with Alzheimer's disease
38. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
39. Rivastigmin
40. Rivastigmin
41. Alkaloids of Galanthus woronowi. II. Isolation of a new alkaloid
42. La galanthamine, puissant cholinergique naturel
43. Cholinesterase inhibition by galanthamine and lycoramine
44. Physostigmine and galanthamin. Probes for a novel binding site on the α-4 β-2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells
45. Une nouvelle medication de la myasthenie et des dystrophies neuro-musculaires: La nivaline
46. Galanthamine in the treatment of patients with cochlear neuritis and ganglionitis
47. Galanthamine treatment in senile dementia of Alzheimer's type: A case report
48. Clinical studies with galanthamine
49. Galanthamine hydrobromide in mania
50. Correction of apatheticabulic manifestations of schizophrenia with cholinotropic drugs
51. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
52. The effect of cholinesterase inhibitors on the secretion of APPs from the brain cortex
53. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease
54. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease
55. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase
56. Preclinical pharmacology of metrifonate: A promise for Alzheimer therapy
57. Metrifonate induces cholinesterase inhibition exclusively via slow release dichlorvos
58. Double-blind, placebo-controlled study of metrofonate, an acetylcholinesterase inhibitor, for Alzheimer's disease
59. Effects of metrifinate on cognitive decline in Alzheimer's disease: A double-blind, placebo-controlled, 6-month study
60. Metrifonate treatment of the cognitive deficits of Alzheimer's disease
61. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
62. Metrifonate: Update on a New Antidementia Agent
63. A potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate
64. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
65. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer's presenile dementia
66. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86
67. Induction of depression with oxotreorine in patients with Alzheimer's disease
68. RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects
69. Multiple-dose Arecoline infusions in Alzheimer's disease
70. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease
71. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease
72. Milameline: Nonselective, partial muscarinic receptor agonist for the treatment of Alzheimer's disease
73. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from chines hamster ovary-m1 cells
74. Pet study of the M1-agonist (11c)xanomeline and (11c)butylthio-TZTP in monkey and man
75. Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
76. Efficacy and safety of SB 20/20/26 as a symptomatic treatment for Alzheimer's disease
77. Selective muscarinic rezeptor agonists and antagonists
78. Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains
79. Decreased protein levels of nicotinic rezeptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease
80. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease
81. RJR-2403: A nicotinic agonist with CNS selectivity. I. In vitro characterization
82. RJR-2403, a nicotinic agonist with CNS selectivity. II. In vivo characterization
83. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents
84. Preliminary evaluation of besperidine for the treatment of Alzheimer's disease. Besperidine study group
85. A treatment and withdrawal trial of bespiridine in Alzheimer's disease
86. Regional distribution of (3H)MK-801 binding sites in the human brain
87. Glutamaterge Behandlungsansatze bei der Alzheimer-Demenz
88. Neue therapeutische Moglichkeiten mit niederaffinen NMDA-Rezeptoragonisten
89. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic pespectives
90. Improved cognition in Alzheimer's disease with short-term d-cycloserine treatment
91. Glutamate, learning and dementia - Selection of evidence
92. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
93. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
94. Psychotogenicity and NMDA receptor antagonism: Implications for neuroprotective pharmacotherapy
95. Wirksamkeit und Vertraglichkeit von Memantine bei Patienten mit dementiellem Syndrom
96. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study
97. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment
98. Memantine in severe dementia results of the M-9-Best study (benefit and efficacy in demented patients during treatment with memantine)
99. Memantin
100. Deposition of βA4 protein along neuronal plasma membranes in diffuse plaques
101. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain
102. Immunologie der degenerativen Demenzen
103. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
104. A case control study of Alzheimer s disease
105. Risk of Alzheimer's disease and duration of NSAID use
106. Clinical trial of indomethacin in Alzheimer's disease
107. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
108. Anti-inflammatory drugs and Alzheimer-type pathology in aging
109. A randomized controlled trial of prednisone in Alzheimer's disease cooperative study
110. Propentofylline depresses amyloid and Alzheimer's CSF microglial antigens after ischaemia
111. Postischaemic glial responses and amyloid accumulation are modified by propentofylline: Neuroprotective pharmacon for Alzheimer's disease
112. Reactive oxygen species and the central nervous system
113. Oxidative damage in neurodegenerative disease
114. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment
115. Free radicals in Alzheimer's disease
116. Neuroprotective therapeutic strategies
117. Is Alzheimer's disease of oxidative stress?
118. Commentary: Alzheimer's disease: A disorder of oxidative stress
119. Central role of exyradicals in the mechanism of amyloid β-peptide cytotoxicity
120. Commentary: Glycoxidation in Alzheimer's disease: A specific mechanism of early lesion pathogenesis?
121. Advanced glycation endproducts - Associated parameters in the blood of patients with Alzheimer's disease
122. Ginko biloba extract (Egb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse
123. Clinical improvement of memory and other cognitive functions by ginko biloba: Review of relevant literature
124. Free radicals in Alzheimer's dementia: Currently available therapeutic strategies
125. Proof of efficacy of the ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infart dementia
126. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American Egb Study Group
127. Idebenone in senile dementia of Alzheimer type: A multicentre study
128. Idebenone, a new drug in the treatment of cognitive impairment in patients of the Alzheimer type
129. Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: A double-blind, placebo-controlled multicentre study
130. Vitamin E as an in vitro and vivo antioxidant
131. Vitamin E
132. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease
133. Ascorbate is an outstanding antioxidant in human blood plasma
134. Interaction of ascorbic acid with the neurotoxic effect of NMDA and sodium nitroprusside
135. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation
136. Effects of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT)
137. The molecular pharmacology of 1-deprenyl
138. Pharmacology of selegiline
139. L-deprenyl in Alzheimer's disease
140. Cognitive effects of 1-deprenyl in Alzheimer's disease
141. Therapie von oxidativem Stress
142. +-treated dopaminergic neurons
143. Dose-dependent effects of deprenyl on CSF metabolites in patients with Alzheimer's disease
144. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer's type. Influence of treatment with 1-deprenyl
145. Lazabemide for the treatment of Alzheimer's disease: Rationale and therapeutic perspectives
146. Oxidative damage in the central nervous system: Protection by melatonin
147. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for Alzheimer's disease
148. Use of estrogens for the prevention and treatment of Alzheimer's disease
149. Postmenopausal hormone therapy and mortality
150. Estrogen use and early onset in Alzheimer's disease: A population-based study
151. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease
152. Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells
153. Estrogen regulates metabolism of Alzheimer amyloid-β-precursor protein
154. Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death
155. Radical scavenging compound J 811 inhibits hydrogen peroxide-induced death of cerebellar granule cells
156. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides
157. Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease
158. Cytochrome c oxidase in Alzheimer's disease
159. Mitochondrialer Stoffwechsel bei Demenz vom Alzheimer Typ
160. Therapy with a combination of coenzyme Q10, vitamin B6 and iron for Alzheimer's disease and senile dementia of Alzheimer type
161. Nicotinamide Adenine Dinucleotide (NADA) - A new therapeutic approach: Preliminary results with cancer patients and patients with dementia of the Alzheimer type
162. Stimulatioin of endogenous 1-dopa biosynthesis - A new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)
163. Senile dementia of Alzheimer's type and Parkinson's disease: Neurochemical verlaps and specific differences
164. Stimulation of dopamine biosynthesis in cultured PC12 phaeochromocytoma cells by the coenzyme nicotinamide adenindinucleotide (NADH)
165. Coenzyme nicotinamide adenine dinucleotide. New therapeutic approach for improving dementia of the Alzheimer type
166. NADH (Nicotinsaure-Adenin-Dinukleotid) und M. Alzheimer
167. Acetyl-L-carnitine as a precursor of acetylcholine
168. Activity of L-carnitine and acetyl-L-carnitine on cholinoceptive neocortical neurons of the rat in vivo
169. Acetyl-L-carnitine and Alzheimer's disease: Pharmacological considerations beyond the cholinergic sphere
170. Long-term acetyl-L-carnitine treatment in Alzheimer's disease
171. Double-blind parallel design pilot study of acetyl-L-carnitine in patients with Alzheimer's disease
172. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
173. Geographical relation between Alzheimer's disease and aluminium in drinking water
174. Neuropathologische, immunologische und psychobiologische Aspekte der Alzheimer-Demenz
175. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide
176. Reactive oxygen species and the central nervous system
177. Blood transferrin and ferritin in Alzheimer's disease
178. Intramuscular desferrioxamine in patients with Alzheimer's disease
179. Lazaroids: Mechanisms of action and implications for disorders of the CNS
180. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case report)
181. Nerve Growth Factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex
182. Neurotropic factors
183. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor
184. An ACTH 4-9 analog (ORG 2766) and cognitive performance: High-dose efficacy and safety in dementia of the Alzheimer's type
185. Efficacy of the petidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)
186. Neural transplantation in animal models of dementia
187. Engeneered cells: A promising therapeutic approach for neural disease
188. A firm base for drug development